LEXINGTON, Mass.--(BUSINESS WIRE)-- Concert Pharmaceuticals, Inc. announced today that Roger Tung, Ph.D., President and Chief Executive Officer of Concert, will present at the 30th Annual J.P. Morgan Healthcare Conference on Tuesday, January 10, 2012 at 1:30 p.m. Pacific Time. The conference will be held January 9-12, 2012 at the Westin St. Francis Hotel in San Francisco.
Concert Pharmaceuticals is a clinical stage biotechnology company focused on applying the company’s DCE Platform™ (deuterated chemical entity platform) to create novel and differentiated small molecule drugs. Concert’s approach leverages decades of pharmaceutical and clinical experience to reduce the time, risk and expense needed to create important new medicines. The company has a broad research pipeline encompassing many therapeutic areas including antiviral disease, renal disease, and CNS disorders, among others. Founded in 2006, Concert has raised more than $110 million of venture and institutional capital. For more information on Concert Pharmaceuticals, please visit www.concertpharma.com.
Concert Pharmaceuticals, the CoNCERT logo and the DCE Platform are trademarks of Concert Pharmaceuticals, Inc.
Concert Pharmaceuticals, Inc.
Justine E. Koenigsberg, 781-674-5284
Senior Director, Corporate Communications and Investor Relations
KEYWORDS: United States North America California Massachusetts
INDUSTRY KEYWORDS: Health Biotechnology Clinical Trials Pharmaceutical Research Science